LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

19.5 -2.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.28

Максимум

20.02

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+72.89% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-433M 2.5B
Предишно отваряне	22
Предишно затваряне	19.5

Настроения в новините

By Acuity

50%

174 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.05.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

F&P Healthcare's Outlook Key for Investors -- Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19.05.2026 г., 22:02 ч. UTC

Печалби

ZTO Express (Cayman): Di Xu to Resign From Board

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19.05.2026 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19.05.2026 г., 21:37 ч. UTC

Печалби

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19.05.2026 г., 21:01 ч. UTC

Печалби

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19.05.2026 г., 20:58 ч. UTC

Печалби

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19.05.2026 г., 20:46 ч. UTC

Горещи акции

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19.05.2026 г., 20:43 ч. UTC

Пазарно говорене

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19.05.2026 г., 20:34 ч. UTC

Печалби

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q EPS 5c >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q Sales $1.4B >JHX

19.05.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5B

19.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19.05.2026 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

72.89% нагоре

12-месечна прогноза

Среден 34.63 USD 72.89%

Висок 36 USD

Нисък 33 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

174 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.